Mr. Erez Tetro reports

VVT MED EXPANDS INTO THE DOMINICAN REPUBLIC, APPOINTING ANTILLES MEDICAL AS EXCLUSIVE DISTRIBUTOR

VVT Med Inc. has entered into the Dominican Republic market through a trial distribution and evaluation agreement with Antilles Medical, a local distributor with established clinical and commercial infrastructure in the region.

Under the agreement, Antilles has been appointed as VVT Med's exclusive distributor for ScleroSafe in the Dominican Republic for an initial evaluation period. The arrangement includes an initial purchase order for ScleroSafe full sets, reflecting Antilles's commercial commitment to the market entry process. The agreement establishes a defined pathway to a full five-year exclusive distribution partnership, subject to the parties reaching mutually agreed terms prior to the conclusion of the evaluation period.

Antilles assumes full responsibilities as both distributor and importer under applicable local regulatory requirements, and its personnel is required to complete a comprehensive training and certification program provided by VVT Med prior to commencing any clinical activity. This structured on-boarding model reflects VVT Med's commitment to quality-controlled commercial expansion and consistent clinical outcomes across markets.

"The Dominican Republic represents another step in our systematic expansion across the Americas," said Erez Tetro, chief executive officer of VVT Med. "We are pleased to partner with Antilles Medical, whose local expertise and market knowledge support the introduction of ScleroSafe to local physicians. We look forward to supporting their team through training and clinical integration as we work toward a long-term commercial relationship."

This agreement extends VVT Med's growing commercial presence across the Americas, complementing the company's established foothold in the United States through its relationship with Northwell Health, and its active distribution platforms in India and South Korea. The Dominican Republic entry follows the treatment of first patients in Italy in May, 2026, underscoring the accelerating pace of ScleroSafe adoption among leading vein specialists globally.

Financing update

As previously announced in the company's news releases dated March 18, 2026, and April 22, 2026, the company completed the first tranche of its non-brokered private placement offering of up to gross proceeds of $3-million, issuing 4,262,654 units at a price of 25 cents per unit for gross proceeds of $1,065,663.50. Each unit consists of one common share of the company and one-half of one common share purchase warrant, with each whole warrant exercisable into one common share at an exercise price of 37.5 cents for a period of 24 months from the date of issuance. The company wishes to provide an update that it intends to close a second tranche of the offering on the same terms on or about July 20, 2026. The net proceeds of the second tranche are expected to be used to support expanded U.S. and global commercialization efforts, product manufacturing to accommodate anticipated demand, working capital, and general corporate purposes. Securities issued under the offering are subject to a four-month hold period from the date of issuance in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The second tranche remains subject to receipt of all necessary regulatory approvals, including the final approval of the TSX Venture Exchange. There can be no assurance that the second tranche will be completed on the terms described or at all.

About VVT Med Inc.

VVT Medical develops, manufactures and distributes minimally invasive, non-thermal, non-tumescent solutions for the treatment of vein diseases, starting with varicose veins. VVT is one of the few Food and Drug Administration-cleared, stand-alone company offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease while enabling physicians to deliver effective, efficient and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.